[¹⁸F]Fluorodeoxyglucose – positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy

References

• Malmstrom PU. Why has the survival of patients with bladder cancer not improved? BJU Int 2008;101:267–9.
   PubMedGoogle Scholar
• Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039–47.
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111–16.
   PubMed Web of Science ®Google Scholar
• Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24:296–304.
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Malmström PU. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297–303.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778–92.
   PubMed Web of Science ®Google Scholar
• Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012;61:810–17.
   PubMed Web of Science ®Google Scholar
• Yaman O, Baltaci S, Arikan N, Yilmaz E, Gogus O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol 1996;78:197–200.
   PubMedGoogle Scholar
• Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 2009;27:3–7.
   PubMed Web of Science ®Google Scholar
• Bolenz C, Herrmann E, Bastian PJ, Michel MS, Wulfing C, Tiemann A, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int 2010;106:493–9.
   PubMedGoogle Scholar
• Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 2012;81:2411–16.
   PubMed Web of Science ®Google Scholar
• Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med 2005;32:1412–17.
   Google Scholar
• Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)–computed tomography (CT) in the staging of bladder cancer. BJU Int 2014;114:389–95.
   PubMed Web of Science ®Google Scholar
• Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, et al. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–9.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811–14.
   PubMed Web of Science ®Google Scholar
• Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Impact of (18)F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 2013;112:729–34.
   PubMedGoogle Scholar
• Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764–70.
   PubMed Web of Science ®Google Scholar
• Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy, 2-(18F)fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991;145:279–83.
   PubMed Web of Science ®Google Scholar
• de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only. Eur J Surg Oncol 2009;35:352–5.
   PubMed Web of Science ®Google Scholar
• Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169:2113–17.
   PubMed Web of Science ®Google Scholar
• Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E, et al. 18F-fluorodeoxyglucose–positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology 2014;83:393–8.
   PubMedGoogle Scholar
• Mertens LS, Fioole-Bruining A, van Rhijn BWG, Kerst JM, Bergman AM, Vogel WV, et al. Adult urology: FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer. J Urol 2013;189:1687–91.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Igarashi M, Tanaka T, Shindo T, Masumori N, Tamakawa M, et al. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. Jpn J Clin Oncol 2012;42:1192–6.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 2012;61:1229–38.
   PubMed Web of Science ®Google Scholar
• Mertens LS, Meijer RP, Meinhardt W, Poel HG, Bex A, Kerst JM, et al. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. BJU Int 2014;114:67–74.
   PubMedGoogle Scholar
• Lusuardi L, Janetschek G. Update on use of enhanced imaging to optimize lymphadenectomy in patients undergoing minimally invasive surgery for urothelial cancer of the bladder. Curr Urol Rep 2013;14:124–9.
   PubMedGoogle Scholar